Your browser doesn't support javascript.
loading
Targeted therapy for fusion-driven high-risk acute leukemia.
Pikman, Yana; Stegmaier, Kimberly.
Afiliación
  • Pikman Y; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA; and.
  • Stegmaier K; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA; and.
Blood ; 132(12): 1241-1247, 2018 09 20.
Article en En | MEDLINE | ID: mdl-30049809
Despite continued progress in drug development for acute leukemias, outcomes for patients with some subtypes have not changed significantly in the last decade. Recurrent chromosomal translocations have long been recognized as driver events in leukemia, and many of these oncogenic fusions portend high-risk disease. Improved understanding of the molecular underpinnings of these fusions, coupled with novel chemistry approaches, now provide new opportunity for therapeutic inroads into the treatment of leukemia driven by these fusions.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia / Proteínas de Fusión Oncogénica / Inhibidores de Proteínas Quinasas / Antineoplásicos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia / Proteínas de Fusión Oncogénica / Inhibidores de Proteínas Quinasas / Antineoplásicos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Año: 2018 Tipo del documento: Article